Janux Therapeutics, Inc. Financing Receivable, Allowance for Credit Loss
Janux Therapeutics, Inc. (JANX) had Financing Receivable, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:FinancingReceivableAllowanceForCreditLosses · last filed 2026-08-06
- 2026-06-30: Financing Receivable, Allowance for Credit Loss $0.00.
- 2026-03-31: Financing Receivable, Allowance for Credit Loss $0.00.
- 2025-12-31: Financing Receivable, Allowance for Credit Loss $0.00.
- 2025-09-30: Financing Receivable, Allowance for Credit Loss $0.00.
| Period end | Financing Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |